# Questions, Without the Sales Pitch > Research Peptide Fundamentals FAQ — Peaceful Peptides — Research Peptide Fundamentals research peptides FAQ covering KPV, NAD+, BPC-157, and GHK-Cu with model-specific, citation-linked answers. **READER QUESTIONS / SOURCE-LED ANSWERS** Direct answers that keep compound identity, experimental model, and evidence maturity in view. ## What is KPV peptide? KPV is the three-amino-acid sequence lysine-proline-valine, corresponding to the C-terminal fragment of alpha-MSH. It is studied as an anti-inflammatory peptide that appears to retain inflammatory signaling effects without the parent hormone’s pigmentary action [5]. The research is preclinical: cells, mice, rabbits, and delivery systems rather than human clinical trials. ## What does KPV peptide do? In intestinal cell and mouse models, KPV enters cells through the PepT1 transporter and reduces NF-kB and MAP-kinase signaling and pro-inflammatory cytokine secretion [3]. Other animal work reports lower colonic inflammation and faster corneal epithelial repair [4][6]. Those are model-specific findings, not demonstrated human benefits. ## What is KPV peptide used for? In published research, KPV is used to investigate inflammatory pathways, experimental colitis, targeted intestinal delivery, and tissue-repair models [1][2][3][6]. It has no FDA-approved therapeutic use, and no published human clinical trial establishes efficacy or safety. ## What is NAD supplement used for? NAD+-related supplements generally aim to raise the body’s NAD+ pool through precursors such as NMN or NR. Human trials show that these precursors can increase blood NAD+ [9][12]. Researchers study whether that changes metabolic or functional endpoints, but evidence for longevity, disease prevention, or broad rejuvenation remains limited [8]. ## What is the downside of taking NAD+? The main evidence problem is form and endpoint confusion. Intact oral NAD+ is not equivalent to studied precursors, and raising a blood biomarker does not guarantee tissue or clinical benefit. Short precursor trials were generally well tolerated [9][12], but they do not settle long-term safety, compounded injectable quality, or context-dependent biological concerns. ## Does NAD cause weight gain? The composed evidence does not establish NAD+-related precursors as a cause of weight gain. In a 10-week NMN trial, muscle insulin sensitivity improved while body composition did not change [10]. That is a narrow study finding, not proof about every formulation or population. ## What does BPC-157 do in the body? Human effects are not established. In preclinical systems, BPC-157 is linked to VEGFR2-driven angiogenesis, endothelial nitric-oxide signaling, and tissue-repair pathways [16]. Animal studies also report gastric protection [17]. A two-person human pilot measured short-term safety markers, not repair efficacy [13]. ## Is BPC-157 a growth hormone? No. BPC-157 is a fifteen-amino-acid research peptide, not growth hormone. Some preclinical work links it to growth-hormone-receptor signaling in tendon cells, but interaction with a pathway does not make it the hormone itself. Its best-characterized mechanism in this corpus is VEGFR2-linked angiogenesis [16]. ## Does BPC-157 work immediately? No controlled human efficacy trial in this corpus establishes that BPC-157 works immediately—or that it produces a therapeutic benefit at any human time point. Rapid-recovery stories from research-use communities are anecdotal, not clinical evidence. Reviews describe human evidence as extremely limited [14]. ## What does a GHK-Cu peptide do? GHK-Cu binds copper and, in laboratory research, influences fibroblast matrix production, remodeling enzymes, and gene-expression pathways [19][21]. Small topical studies and reviews report collagen-related skin signals, while a combination hair study reported increased hair counts [18][20]. These findings do not establish systemic anti-aging effects. ## Is GHK-Cu peptide really anti-aging? “Anti-aging” is broader than the evidence. Reviews summarize small topical improvements and biological mechanisms relevant to skin remodeling [18][21], but delivery through the outer skin layer is limited and systemic use lacks validated human data. The defensible claim is that GHK-Cu has topical and preclinical aging-related research, not that it reverses aging. ## What is the difference between GHK and GHK-Cu? GHK is the free tripeptide glycyl-histidyl-lysine. GHK-Cu is that peptide coordinated to a copper ion. Copper binding is central to many reported biological activities, so the forms should not be treated as interchangeable. Study attribution also matters: a product containing GHK alongside another active is not a pure GHK-Cu experiment [20]. --- An independent evidence ledger for four often-overstated compounds—measured findings and uncertainty, never a prescription.